Heparin is currently on the FDA's drug shortage list.
Energy and Commerce chairman Frank Pallone, a Democrat, and its top
Republican, Greg Walden, and four other bipartisan leaders said in a
letter seen by Reuters that they seek information on "any
contingency plans in the event of a serious shortage" and a briefing
from FDA on its plans to address it.
About 60 percent of the crude heparin used to make finished heparin
in the United states is sourced from China, the letter said.
The FDA said it has been monitoring the issue since 2018 "and has
followed up with heparin suppliers. At this time we do not
anticipate supply issues."
In March 2018, the FDA said it encouraged the reintroduction of
alternative sources of heparin. Until the 1990s, the United States
used sources of heparin produced from bovine sources until concerns
were raised about "Mad Cow" disease.
"The FDA has been in contact with several companies, both domestic
and foreign, regarding reintroduction of bovine heparin to the U.S.
market. The details of those conversations are confidential," the
agency said on Tuesday.
[to top of second column] |
Heparin, which the letter said is the only anticoagulant drug used
in the United States for open heart surgeries and kidney dialysis,
is derived from pig intestines.
African swine fever, for which there is no cure and no vaccine,
kills almost all infected pigs but does not harm people. The virus
is similar to the strain found in recent years in Russia, Georgia
and Estonia.
As many as half of China’s breeding pigs have either died from
African swine fever or been slaughtered because of the disease,
industry insiders estimate. The World Organization for Animal Health
said in May it will take years for China, the world’s biggest pork
producer, to contain the virus.
The United States has previously had heparin shortages, as recently
as when Baxter International Inc.'s supply was impacted by the
effect of Hurricane Maria on its manufacturing facilities in Puerto
Rico.
(Reporting by David Shepardson; Editing by Dan Grebler)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |